Clinigen gains US FDA approval for Foscavir in HIV/AIDS-related cytomegalovirus infections and herpes
- Mature brand acquired from AstraZeneca positioned as key growth driver
- Hospira granted exclusive rights to market, promote and distribute Foscavir in the US
- Clinigen signs exclusive distribution and marketing agreement with BL&H in South Korea
Clinigen Healthcare, the pharmaceutical products division of Clinigen Group, announced today that its supplemental new drug application (sNDA) for Foscavir (foscarnet sodium), a treatment for HIV/AIDS-related cytomegalovirus (CMV) infections and herpes, has been approved by the US Food and Drug Administration (FDA).
Clinigen appointed Hospira (NYSE: HSP) to distribute Foscavir to US patients on an emergency supply basis in September 2011. Now that FDA approval has been received, Hospira has the exclusive rights to market, promote and distribute Foscavir in the US pursuant to the License and Distribution Agreement executed by Hospira and Clinigen in July 2011.
Peter George, chief executive of Clinigen Group, commented: “Since we acquired global rights to Foscavir, a mature brand from AstraZeneca, in March 2010 our growth strategy for the product has included work on its price, the label and its availability in different geographical markets. We’ve already established good penetration across Europe, but because we didn’t initially have a US license, the country’s contribution to overall Foscavir sales has been relatively modest. Being granted an sNDA in the world’s largest pharmaceutical market will be key to meeting our ambitious growth projections.”
Global Foscavir revenues grew six-fold in 2010-2011 and Clinigen expects another doubling in sales by the end of the current financial year.
Separately, Clinigen has signed an agreement granting South Korea’s BL&H Co exclusive rights to market and distribute Foscavir locally. Clinigen and BL&H are collaborating to secure Korean marketing authorizations for Foscavir, both in its primary indications and as a treatment for CMV in hematopoietic stem cell transplant (HSCT) patients (bone marrow transplants). The companies expect a decision from the Korea Food and Drug Administration (KFDA) by the end of 2012.
“We’re excited about entering South Korea, not only because of the country’s status as a fast-growing emerging market but, crucially, because it is a world leader in the field of stem cell research,” said Jim Curtis, business development director at Clinigen. “As we establish relationships with local researchers, we will acquire valuable insights that will inform our approach in other key markets around the world.”
Clinigen is in on-going discussions with key opinion leaders in the field of bone marrow transplantation and with the regulatory authorities, with the aim of adding CMV in bone marrow transplant patients to Foscavir’s European label later this year. Foscavir received its first marketing authorization for use in the HSCT setting from Japan’s Ministry of Health Labor and Welfare (MHLW) in July 2011.
About Foscavir
Foscavir (foscarnet sodium) is licensed to treat cytomegalovirus (CMV) retinitis in HIV patients and acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immune-compromised patients in: Australia, Belgium, France, Germany, Hungary, Israel, Italy, Japan, Luxembourg, Mexico, the Netherlands, New Zealand, Singapore, Spain, Switzerland, the UK and the US. In Japan, Foscavir is also indicated for the treatment of CMV in hematopoietic stem cell transplant patients.
About Clinigen
Clinigen Group was formed by merger in 2010 to create a specialty pharmaceutical and pharmaceutical services company focused on getting medicines to physicians and their patients. The merger brought together three companies: Clinigen CTS (formerly Keats Healthcare) and Clinigen GAP, which make up Clinigen’s services division, and Clinigen Healthcare, the group’s products business.
Clinigen Group is headquartered in Burton-on-Trent, UK, with offices in Philadelphia, US, and Tokyo, Japan.
For more information visit: www.clinigengroup.com
Contact:
Tudor Reilly
Pete Chan
Office: +44(0) 207 034 3208
Mobile:
+44(0)7725 554 632
Email: pete.chan@tudor-reilly.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 12:50:00 CEST | Press release
Revenue of $8.49 billion decreased 3% year on year GAAP EPS of $0.58 decreased 22% year on year EPS, excluding charges and credits, of $0.72 decreased 4% year on year Net income attributable to SLB of $797 million decreased 25% year on year Adjusted EBITDA of $2.02 billion decreased 2% year on year Cash flow from operations of $660 million increased $333 million year on year Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9%
Corona, The World’s Most Valuable Beer Brand1, Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press release
Brand Invites The World to Join the Celebration with Experiences at the Most Epic Beaches on EarthGlobal “Corona 100” Platform Launches with a Legendary Concert at Copacabana Beach, Featuring One of the World’s Top Musical Artists with Millions in Attendance Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive l
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 09:28:00 CEST | Press release
Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom